Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

CNBX Pharmaceuticals (CNBX) EBT Margin (2016 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed EBT Margin for 11 consecutive years, with 507.98% as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, EBT Margin changed N/A year-over-year to 507.98%, compared with a TTM value of 1102.63% through Nov 2024, down 95121.0%, and an annual FY2024 reading of 466.09%, down 23902.0% over the prior year.
  • EBT Margin was 507.98% for Q1 2024 at CNBX Pharmaceuticals, down from 192.2% in the prior quarter.
  • Across five years, EBT Margin topped out at 1461.33% in Q2 2022 and bottomed at 66134.96% in Q1 2020.
  • Average EBT Margin over 4 years is 14915.33%, with a median of 507.98% recorded in 2024.
  • Peak annual rise in EBT Margin hit 1721654bps in 2020, while the deepest fall reached -2751225bps in 2020.
  • Year by year, EBT Margin stood at 30390.26% in 2020, then surged by 95bps to 1643.99% in 2022, then soared by 88bps to 192.2% in 2023, then plummeted by -164bps to 507.98% in 2024.
  • Business Quant data shows EBT Margin for CNBX at 507.98% in Q1 2024, 192.2% in Q4 2023, and 161.5% in Q3 2023.